8月19日，亚辉龙今日收盘15.39元，下跌1.54%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到35.74倍，总市值87.79亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均59.49倍，行业中值40.19倍，亚辉龙排名 第69位。 股东方面，截至2025年3月31日，亚辉龙股东户数12415户，较上次增加285户，户均持股市值35.28万 元，户均持股数量2.76万股。 深圳市亚辉龙生物科技股份有限公司的主营业务是以化学发光免疫分析法为主的体外诊断仪器及配套试 剂的研发、生产和销售，及部分非自产医疗器械产品的代理销售业务。公司的主要产品是自产试剂（非 新冠产品）、自产仪器（非新冠产品）、自产耗材（非新冠产品）、自产新冠产品、软件服务、代理试 剂、代理仪器、代理耗材。公司自主研发了磁微粒吖啶酯直接化学发光免疫诊断技术，研制了包括仪器 和配套试剂在内的全自动免疫分析系统，打破了国外巨头在吖啶酯直接发光领域的技术垄断，成为国内 较早实现磁微粒吖啶酯化学发光免疫分析仪及配套试剂产业化的企业，填补了国内市场空白。公司质量 体系建设达到国际标准，主要产品已通过ISO9001认证、ISO ...

Core Viewpoint - The company, 亚辉龙, is experiencing a decline in revenue and net profit, with a significant drop in net profit year-over-year, indicating potential challenges in its financial performance [2]. Group 1: Company Overview - 亚辉龙 specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, primarily using chemiluminescence immunoassay technology [2]. - The company has developed a fully automated immunoassay system, breaking the technological monopoly of foreign giants in the field of acridine ester direct chemiluminescence [2]. - The quality management system of the company meets international standards, with major products certified by ISO9001, ISO13485, and EU CE [2]. Group 2: Financial Performance - For the first quarter of 2025, the company reported revenue of 4.18 billion yuan, a year-over-year decrease of 3.13%, and a net profit of 10.14 million yuan, down 84.63% year-over-year [2]. - The gross profit margin for the company stands at 59.49% [2]. Group 3: Market Position - As of July 18, the company's stock price closed at 15.07 yuan, with a rolling PE ratio of 34.99, marking a new low in 30 days [1]. - The average PE ratio for the medical device industry is 52.34, with a median of 36.99, placing 亚辉龙 at the 72nd position in the industry ranking [1][3]. - The total market capitalization of the company is 8.596 billion yuan [1].

序号股票简称PE(TTM)PE(静)市净率总市值(元)70亚辉龙28.2128.213.2185.11亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56-2672.561.6719.88亿2硕世生 物-1835.15-1835.151.1537.91亿3诺唯赞-549.11-549.112.5299.35亿4博晖创新-335.30-206.443.6951.46亿5康 泰医学-262.5830.812.6851.07亿6华大基因-197.28215.792.04200.47亿7奥精医疗-108.26-108.261.3819.61亿 8睿昂基因-79.59-79.591.2411.51亿9热景生物-60.65-60.653.33108.69亿10华大智造-52.74-52.743.96315.97 亿11中红医疗-48.32-32.870.7743.02亿 来源：金融界 截至2024年三季报，共有123家机构持仓亚辉龙，其中基金123家，合计持股数5552.45万股，持股市值 8.77亿元。 深圳市亚辉龙生物科技股份有限公司的主营业 ...